# The science behind cannabis cravings and the booming munchies market > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/the-science-behind-cannabis-cravings-and-the-booming-munchies-market/ > **Published:** 2026-05-20T10:16:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:41-04:00 > **Clinical Summary:** THC appetite regulation through endocannabinoid system: clinical mechanism, therapeutic uses in cachexia, and metabolic risk counseling for patients. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. THCResearchNeurologyIndustrySafetyMental HealthDosing Why This Matters Clinicians treating patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) or monitoring those using cannabis therapeutically need to understand THC’s direct neurobiological effects on appetite and eating behavior to properly counsel patients on weight management and metabolic health risks. This evidence base also helps clinicians distinguish between cannabis-induced appetite changes and other causes of weight gain or eating disorders in their patient populations. Understanding these mechanisms informs personalized treatment strategies and allows clinicians to set realistic expectations with patients about cannabis’s metabolic effects. Clinical Summary Recent clinical studies have established that THC activates endocannabinoid receptors in brain regions governing appetite regulation and food reward, directly stimulating hunger and food-seeking behavior independent of nutritional need. This neurobiological mechanism explains the well-documented “munchies” effect and has significant implications for patients using cannabis therapeutically, particularly those with cachexia, chemotherapy-induced anorexia, or HIV-related weight loss, where [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) may be beneficial. Conversely, clinicians should counsel patients with metabolic disorders, obesity, or eating disorders that cannabis use may exacerbate these conditions through altered appetite control and increased caloric consumption. The emerging commercial market capitalizing on cannabis-induced appetite changes reflects growing clinical recognition of this effect, though it also highlights the need for patient education about managing this side effect when [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) is not therapeutically desired. Clinicians prescribing cannabis should screen patients for conditions where increased appetite could be harmful and discuss strategies to mitigate unwanted weight gain or metabolic effects. Understanding the pharmacologic basis of cannabis-related [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) allows clinicians to better counsel patients on realistic expectations and help identify which patient populations may benefit most from this effect while managing risks in others. Dr. Caplan’s Take “What we’re seeing in the literature now is that THC’s effects on appetite aren’t incidental or anecdotal, they’re neurobiologically precise, and that matters because some of my patients genuinely need this mechanism for medical reasons – whether they’re managing cachexia from cancer or struggling with appetite loss from other conditions – while others may be using it recreationally without understanding they’re engaging a powerful appetite system that wasn’t designed for modern food environments.” Clinical Perspective The emerging mechanistic evidence that THC stimulates appetite through endocannabinoid signaling has clinical relevance for both therapeutic applications and patient counseling. Clinicians should recognize that cannabis-induced appetite stimulation is not merely behavioral or psychological but involves demonstrable neurobiological pathways, which may help validate patients’ subjective experiences while also explaining why certain individuals are more susceptible to increased consumption patterns. However, this understanding should be contextualized within the broader landscape of individual variability in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/), product potency, frequency of use, and concurrent medications that may amplify or attenuate these effects. For clinicians advising patients on cannabis use, particularly those with eating disorders, metabolic conditions, or addiction vulnerabilities, explicitly discussing appetite changes and the [neurobiological mechanisms](https://cedclinic.com/cannabis-tolerance-behavioral-models/) underlying cravings can improve shared decision-making and help patients anticipate and manage these effects more effectively. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20science%20behind%20cannabis%20cravings%20and%20the%20booming%20munchies%20market%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55818)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55818)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20science%20behind%20cannabis%20cravings%20and%20the%20booming%20munchies%20market%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55818)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.bakeryandsnacks.com/Article/2026/05/20/the-science-behind-cannabis-cravings-and-the-booming-munchies-market/](https://www.bakeryandsnacks.com/Article/2026/05/20/the-science-behind-cannabis-cravings-and-the-booming-munchies-market/) Further Reading Research Digest[Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) Evidence Watch[Cannabinoids in Mental Health Treatment: A Systematic Review and Meta-Analysis](https://cedclinic.com/cannabinoids-mental-health-substance-use-disorders-review/) Cannabis Policy WireCED Regulatory Digest, Since Last Digest, 1 items [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).